{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:59:45Z","timestamp":1792627185386,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11523-023-01001-4","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T09:02:25Z","timestamp":1695632545000},"page":"885-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Na\u00efve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience"],"prefix":"10.1007","volume":"18","author":[{"given":"Danilo","family":"De Novellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Della Pepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Cetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Amendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Delle Cave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Morini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mettivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trastulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"La Magna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Rascato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Carobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Cuffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuigia","family":"Iannalfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Svanera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pizzuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Frigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"issue":"9","key":"1001_CR1","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","volume":"32","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883\u201398.","journal-title":"Leukemia"},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"1026251","DOI":"10.3389\/fonc.2022.1026251","volume":"12","author":"R Iula","year":"2022","unstructured":"Iula R, De Novellis D, Trastulli F, Della Pepa R, Fontana R, Carobene A, et al. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: a multicentric real-life experience. Front Oncol. 2022;12:1026251.","journal-title":"Front Oncol"},{"issue":"7","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3390\/biomedicines10071657","volume":"10","author":"D De Novellis","year":"2022","unstructured":"De Novellis D, Fontana R, Carobene A, Serio B, Ferrara I, Martorelli MC, et al. Serum Free light-chain ratio at diagnosis is associated with early renal damage in multiple myeloma: a case series real-world study. Biomedicines. 2022;10(7):1657.","journal-title":"Biomedicines."},{"issue":"1","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","volume":"25","author":"S Deaglio","year":"2001","unstructured":"Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1\u201312.","journal-title":"Leuk Res"},{"issue":"1","key":"1001_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ijms24010645","volume":"24","author":"D De Novellis","year":"2022","unstructured":"De Novellis D, Fontana R, Giudice V, Serio B, Selleri C. Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance. Int J Mol Sci. 2022;24(1):645.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1001_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37\u201344.","journal-title":"Blood"},{"issue":"22","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"issue":"14","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088\u201396.","journal-title":"Haematologica"},{"issue":"10192","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338.","journal-title":"Lancet"},{"issue":"3","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4103\/apjon.apjon_9_18","volume":"5","author":"T King","year":"2018","unstructured":"King T, Jagger J, Wood J, Woodrow C, Snowden A, Haines S, et al. Best practice for the administration of daratumumab in multiple myeloma: Australian myeloma nurse expert opinion. Asia Pac J Oncol Nurs. 2018;5(3):270\u201384.","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"8","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med"},{"issue":"7","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JOP.18.00143","volume":"14","author":"AK Nooka","year":"2018","unstructured":"Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S. Managing infusion reactions to new monoclonal antibodies in multiple myeloma: daratumumab and elotuzumab. J Oncol Pract. 2018;14(7):414\u201322.","journal-title":"J Oncol Pract"},{"issue":"8","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/j.clml.2022.03.006","volume":"22","author":"JA Davis","year":"2022","unstructured":"Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. \u2018Fast but not so Furious\u2019: short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy. Clin Lymphoma Myeloma Leuk. 2022;22(8):e680\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Rel. 2006;114(2):230\u201341.","journal-title":"J Control Rel"},{"issue":"8","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood.2019000667","volume":"134","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668\u201377.","journal-title":"Blood"},{"issue":"5","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.16980","volume":"192","author":"A Chari","year":"2021","unstructured":"Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021;192(5):869\u201378.","journal-title":"Br J Haematol"},{"issue":"10","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","volume":"107","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022;107(10):2408\u201317.","journal-title":"Haematologica"},{"issue":"5","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370\u201380.","journal-title":"Lancet Haematol."},{"issue":"12","key":"1001_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"S1","key":"1001_CR21","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.5045\/br.2020.S009","volume":"55","author":"Y Koh","year":"2020","unstructured":"Koh Y. AL amyloidosis: advances in diagnosis and management. Blood Res. 2020;55(S1):S54\u20137.","journal-title":"Blood Res."},{"issue":"17","key":"1001_CR22","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","volume":"129","author":"M Delforge","year":"2017","unstructured":"Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359\u201367.","journal-title":"Blood"},{"issue":"8","key":"1001_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"10","key":"1001_CR24","doi-asserted-by":"publisher","first-page":"e777","DOI":"10.1016\/j.clml.2020.05.024","volume":"20","author":"DC Moore","year":"2020","unstructured":"Moore DC, Arnall JR, Thompson DL, Martin AL, Robinson J, Ndiaye A, et al. Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab. Clin Lymphoma Myeloma Leuk. 2020;20(10):e777\u201381.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01001-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-01001-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01001-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T09:19:48Z","timestamp":1700644788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-01001-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-01001-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"8 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Salerno within the CRUI-CARE Agreement. No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Danilo De Novellis, Raffaele Fontana, Salvatore Palmieri, Roberta Della Pepa, Maria Di Perna, Giusy Cetani, Daniela Esposito, Angela Amendola, Giuseppe Delle Cave, Bianca Serio, Denise Morini, Michela Rizzo, Laura Mettivier, Fabio Trastulli, Stefano Rocco, Anastasia Pagano, Serafina Barbato, Aldo Leone, Martina La Magna, Rosario Bianco, Gabriella Rascato, Angela Carobene, Bianca Cuffa, Marialuigia Iannalfo, Valentina Giudice, Gino Svanera, Mario Annunziata, Michele Pizzuti, Ferdinando Frigeri, Catello Califano, Felicetto Ferrara, Fabrizio Pane, and Carmine Selleri declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocol was approved by the local ethic committee (Ethics Committee \u201cCampania Sud,\u201d Brusciano, Naples, Italy; prot.\/SCCE n. 24988).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in accordance with the Declaration of Helsinki (World Medical Association 2013) and protocols were approved by the local ethic committee (Ethics Committee \u201cCampania Sud,\u201d Brusciano, Naples, Italy; prot.\/SCCE n. 24988).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conenst to publish"}},{"value":"Data are available upon request of the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The authors declare that the material is original, has not been published before, nor is under consideration in any other journal.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements"}},{"value":"Conceptualization: D.D.N., B.S., and C.S.; clinical data: D.D.N., R.F., S.P., R.D.P., M.D.P., G.C., D.E., A.A., G.D.C., B.S., D.M., M.R., L.M., F.T., S.R., A.P., S.B., A.L., M.L.M., R.B., G.R., A.C., B.C., M.I., V.G., G.V., M.A., M.P., F.Fr., C.C., F.P., F.Fe., and C.S.; methodology: D.D.N. and V.G.; writing\u2014original draft preparation: D.D.N. and V.G.; writing\u2014review and editing: C.S. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}